Inloggen
E-mail
Wachtwoord
Bewaren
Bent u uw wachtwoord vergeten?
Gratis lid worden
Registreer
Registreer
Instellingen
Instellingen
Dynamische koersen 
OFFON
  1. Homepagina
  2. Aandelen
  3. Nederland
  4. Euronext Amsterdam
  5. Galapagos NV
  6. Nieuws
  7. Persberichten
    GLPG   BE0003818359

GALAPAGOS NV

(GLPG)
Real-time koersen. Real Time Euronext Amsterdam - 28/07 17:35:17
51.55 EUR   +2.69%
15/07Resultaten studies Galapagos niet voldoende
AM
15/07KBC Securities verlaagt koersdoel Galapagos
AM
14/07Positieve resultaten Galapagos studie bij psoriasispatiënten
AM
OverzichtKoersenGrafiekenNieuwsRatingenAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproducten 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiŽle publicatiesSectornieuwsAnalyse MarketScreener
Communiquťs de presse de la sociťtť GALAPAGOS NV
15/07GALAPAGOS : N.V., - Galapagos reports positive topline results with selective TY..
PU
15/07GALAPAGOS : N.V., - Galapagos demonstrates early clinical activity with SIK2/3 i..
PU
14/07GALAPAGOS : demonstrates early clinical activity with SIK2/3 inhibition in infla..
PU
14/07GALAPAGOS : reports positive topline results with selective TYK2 inhibitor GLPG3..
PU
14/07Galapagos meldt positieve resultaten met selectieve TYK2-remmer GLPG3667 in f..
GL
14/07Galapagos toont vroege klinische activiteit aan met SIK2/3-remmer bij ontste..
GL
14/07GALAPAGOS : demonstrates early clinical activity with SIK2/3 inhibition in infla..
AQ
14/07GALAPAGOS : reports positive topline results with selective TYK2 inhibitor GLPG3..
AQ
10/07Galapagos maakt nieuwe data bekend die een snelle symptoomverbetering en aanh..
GL
10/07GALAPAGOS : announces new data supporting rapid symptom improvement and sustaine..
AQ
23/06GALAPAGOS : announces departure of CSO Piet Wigerinck later this year (Form 6-K)
PU
22/06Galapagos kondigt vertrek van Chief Scientific Officer Piet Wigerinck aan lat..
GL
08/06GALAPAGOS : increases share capital through subscription right exercises (Form 6..
PU
07/06Galapagos increases share capital through subscription right exercises
GL
04/06GALAPAGOS : SELECTION study on filgotinib in ulcerative colitis published in The..
PU
04/06SELECTION-studie naar filgotinib bij colitis ulcerosa, gepubliceerd in The La..
GL
28/05GALAPAGOS : to present data on rheumatoid arthritis at the upcoming European Lea..
PU
27/05Galapagos presenteert tijdens het congres van de European League Against Rheu..
GL
19/05GALAPAGOS : announces first patient enrolled in FILOSOPHY study to advance under..
PU
18/05Galapagos announces first patient enrolled in FILOSOPHY study to advance unde..
GL
11/05GALAPAGOS : refocuses pipeline and rightsizes operations (Form 6-K)
PU
06/05Galapagos heroriënteert pijplijn en stroomlijnt organisatie
GL
04/05Transparantieverklaring ontvangen van The Capital Group
GL
04/05GALAPAGOS : Transparency notification received from The Capital Group
AQ
03/05GALAPAGOS : creates new subscription right plans
PU
30/04Galapagos creëert nieuwe inschrijvingsrechtenplannen
GL
28/04GALAPAGOS : Written questions and answers
PU
23/04Gilead Sciences dient goedkeuringsaanvraag in Japan in voor filgotinib voor d..
GL
08/04GALAPAGOS : Extension of lock-up period in Gilead-Galapagos collaboration agreem..
AQ
08/04Verlenging van de lock-up-periode in samenwerkingsovereenkomst tussen Gilead ..
GL
26/03GALAPAGOS NV : - Publication of the annual report and invitation to the ordinary..
AQ
25/03GALAPAGOS : Statutory auditor's report on the non-consolidated financial stateme..
PU
25/03GALAPAGOS : Publication of the annual report and invitation to the ordinary shar..
AQ
25/03Publicatie van het jaarverslag en uitnodiging voor de gewone algemene vergade..
GL
24/03Galapagos appoints Bart Filius as President and Chief Operating Officer
GL
19/03GALAPAGOS : increases share capital through subscription right exercises
AQ
19/03Galapagos verhoogt kapitaal door uitoefening van inschrijvingsrechten
GL
18/03Oxurion NV Business and Financial Update, FY 2020
AQ
04/03GALAPAGOS NV : - Transparency notification received from The Capital Group
AQ
04/03GALAPAGOS : REPORTS PRIMARY ENDPOINT FOR THE ONGOING FILGOTINIB MANTA AND MANTA-..
AQ
04/03Galapagos kondigt primaire eindpunt aan van de lopende MANTA en MANTA-RAy ve..
GL
03/03Transparency notification received from The Capital Group
GL
19/02GALAPAGOS NV : - Pipeline and capital for growth
AQ
18/02Pipeline and capital for growth
GL
10/02Galapagos and Gilead discontinue ISABELA Phase 3 trials in IPF
GL
10/02GALAPAGOS NV : - The Capital Group holds 10.03% of Galapagos shares
AQ
09/02GALAPAGOS : The Capital Group holds 10.03% of Galapagos shares
AQ
09/02The Capital Group bezit 10,03% van de Galapagos aandelen
GL
22/01GALAPAGOS NV : - NICE recommends Jyseleca on NHS in landmark decision for rheuma..
AQ
21/01GALAPAGOS : NICE recommends Jyselecaģ ▼(filgotinib) on NHS in landmark dec..
AQ
21/01NICE BEVEELT JYSELECAģ▼ (FILGO : belangrijke beslissing voor behandeling r..
GL
12/01GALAPAGOS NV : - Gilead holds 25.54% of Galapagos shares
AQ
11/01Gilead holds 25.54% of Galapagos shares
GL
06/01Galapagos geeft presentatie op 39ste jaarlijkse J.P. Morgan Healthcare Confer..
GL
06/01GALAPAGOS : to present at 39th Annual J.P. Morgan Healthcare Conference
AQ
04/01Selvita completes acquisition of Fidelta from Galapagos
GL
2020Galapagos' CEO†doneert Ä10 miljoen in de vorm van persoonlijke aandelen aan A..
GL
2020GILEAD SCIENCES : and Galapagos Announce New Commercialization and Development A..
AQ
2020GALAPAGOS : Gilead and Galapagos Announce New Commercialization and Development ..
BU
2020Gilead †and †Galapagos †announce† New† Commercialization †and† Development† A..
GL
2020Galapagos verhoogt kapitaal door uitoefening van inschrijvingsrechten
GL
2020Galapagos kondigt de eerste dosering met GLPG2737 aan van patiënten met polyc..
GL
2020GALAPAGOS : reports positive topline results with GLPG1205 in IPF patients in PI..
AQ
2020Galapagos reports positive topline results with GLPG1205 in IPF patients in P..
GL
2020GALAPAGOS : Selvita to acquire Fidelta from Galapagos
AQ
2020GALAPAGOS : Selvita to acquire Fidelta from Galapagos
AQ
2020Selvita neemt Fidelta over van Galapagos
GL
2020GALAPAGOS : First patient dosed with GLPG3667 in psoriasis patient Phase 1b tria..
AQ
2020GALAPAGOS : First patient dosed with GLPG3667 in psoriasis patient Phase 1b tria..
AQ
2020First patient dosed with GLPG3667 in psoriasis patient Phase 1b trial
GL
2020OXURION NV Confirms New Patents for THR-687 Issued by European and US Patent ..
AQ
2020GALAPAGOS : OncoArendi and Galapagos enter into exclusive collaboration on chiti..
AQ
2020GALAPAGOS : OncoArendi and Galapagos enter into exclusive collaboration on chiti..
AQ
2020OncoArendi and Galapagos enter into exclusive collaboration on chitinase inhi..
GL
2020GALAPAGOS : reports Q3 2020 results
AQ
1  2  3  4  5  6  7Volgende
Volgende evenement op GALAPAGOS NV
Komende gebeurtenissen in de sector